MX2022003598A - Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. - Google Patents
Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.Info
- Publication number
- MX2022003598A MX2022003598A MX2022003598A MX2022003598A MX2022003598A MX 2022003598 A MX2022003598 A MX 2022003598A MX 2022003598 A MX2022003598 A MX 2022003598A MX 2022003598 A MX2022003598 A MX 2022003598A MX 2022003598 A MX2022003598 A MX 2022003598A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- prevention
- treatment
- pharmaceutical composition
- bone disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que incluye una proteína galectina 9 recombinante estabilizada para la prevención o el tratamiento de una enfermedad ósea, particularmente se relaciona con una composición farmacéutica para la prevención o el tratamiento de una enfermedad ósea, incluida la artritis reumatoide, que incluye una proteína galectina 9 recombinante estabilizada, en la que los péptidos enlazantes son eliminados y los aminoácidos de los dominios C-terminal son eliminados o sustituidos, como ingrediente activo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190143752 | 2019-11-11 | ||
| KR1020200149295A KR102267413B1 (ko) | 2019-11-11 | 2020-11-10 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 |
| PCT/KR2020/015782 WO2021096217A1 (ko) | 2019-11-11 | 2020-11-11 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003598A true MX2022003598A (es) | 2022-06-08 |
Family
ID=75912133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003598A MX2022003598A (es) | 2019-11-11 | 2020-11-11 | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220372088A1 (es) |
| EP (1) | EP4059511A4 (es) |
| JP (2) | JP7468930B2 (es) |
| AU (1) | AU2020384824B2 (es) |
| MX (1) | MX2022003598A (es) |
| WO (1) | WO2021096217A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240032668A (ko) * | 2022-08-31 | 2024-03-12 | (주)지바이오로직스 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 루푸스 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003189874A (ja) * | 2001-12-28 | 2003-07-08 | Galpharma Co Ltd | ガレクチン−９活性制御剤 |
| US8268324B2 (en) | 2004-03-29 | 2012-09-18 | Galpharma Co., Ltd. | Modified galectin 9 proteins and use thereof |
| JP2007291022A (ja) * | 2006-04-26 | 2007-11-08 | Galpharma Co Ltd | 軟骨分化促進作用 |
| WO2010084999A1 (en) * | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| WO2012077811A1 (ja) * | 2010-12-09 | 2012-06-14 | 株式会社ガルファーマ | ガレクチン９を分泌する細胞、その製造方法及びその用途 |
| JP5888761B2 (ja) * | 2012-11-20 | 2016-03-22 | 国立大学法人 香川大学 | ガレクチン９の改変タンパク質 |
-
2020
- 2020-11-11 WO PCT/KR2020/015782 patent/WO2021096217A1/ko unknown
- 2020-11-11 US US17/763,902 patent/US20220372088A1/en active Pending
- 2020-11-11 AU AU2020384824A patent/AU2020384824B2/en active Active
- 2020-11-11 EP EP20887590.6A patent/EP4059511A4/en active Pending
- 2020-11-11 MX MX2022003598A patent/MX2022003598A/es unknown
- 2020-11-11 JP JP2022516730A patent/JP7468930B2/ja active Active
-
2024
- 2024-01-19 JP JP2024006967A patent/JP2024041993A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20220372088A1 (en) | 2022-11-24 |
| EP4059511A1 (en) | 2022-09-21 |
| JP7468930B2 (ja) | 2024-04-16 |
| EP4059511A4 (en) | 2024-01-24 |
| WO2021096217A1 (ko) | 2021-05-20 |
| AU2020384824A1 (en) | 2022-04-14 |
| JP2022548279A (ja) | 2022-11-17 |
| JP2024041993A (ja) | 2024-03-27 |
| AU2020384824B2 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoshikawa | Bioactive peptides derived from natural proteins with respect to diversity of their receptors and physiological effects | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| Fan et al. | Identification and characterization of gastrointestinal-resistant angiotensin-converting enzyme inhibitory peptides from egg white proteins | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| JP2017528419A5 (es) | ||
| HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
| EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| ATE169304T1 (de) | Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung | |
| MXPA01007956A (es) | Polipeptido antimicrobiano/neutralizador de endotoxina. | |
| HRP20110386T1 (hr) | Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2020008902A (es) | Analogos de compstatina y sus usos medicos. | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2022003598A (es) | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. | |
| ATE211391T1 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | |
| Ryu et al. | Potential beneficial effects of marine peptide on human neuron health | |
| PE20221663A1 (es) | Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano | |
| BR112021016571A2 (pt) | Peptídeo isolado, composição farmacêutica, dispositivo médico implantável, uso de um peptídeo e biomaterial de preenchimento ósseo | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| MX2020010030A (es) | Metodos y composiciones que comprenden proteina d tensoactiva (sp-d). |